Acta Pharm. 67 (2017) 1-13
Review
The role of peroxisome
proliferator-activated receptor in the treatment of
non-alcoholic fatty liver diseases
XIN SUN,
YAN ZHANG and MEILIN XIE
yaoxue2030@163.com, xiemeilin@suda.edu.cn
1 Department of
Pharmacy, Wuxi No. 2 People´sa
Hospital, The Affiliated Hospital of Nanjing Medical University, Wuxi, Jiangsu,
214002, China
2 Department of
Gynecology and Obstetrics, Wuxi Maternal and Child Health Hospital, The
Affiliated Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214002, China
3 Department of
Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou,
Jiangsu, 215123, China
Accepted October 6, 2016
Published online October 17,
2016
Non-alcoholic fatty liver disease (NAFLD) has been defined as a spectrum of histological abnormalities and is characterized by significant and excessive accumulation of triglycerides in the hepatocytes in patients without alcohol consumption or other diseases. Current studies are targeting new molecular mechanisms that underlie NAFLD and associated metabolic disorders. Many therapeutic targets have been found and used in clinical studies. Peroxisome proliferator-activated receptors (PPARs) are among the potential targets and have been demonstrated to exert a pivotal role in modulation of NAFLD. Many drugs developed so far are targeted at PPARs. Thus, the aim of this paper is to summarize the roles of PPARs in the treatment of NAFLD.
Keywords: non-alcoholic fatty liver disease, peroxisome
proliferator-activated receptors, agonists, insulin
resistance, inflammation